circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Cytokinetics, Inc. Annual Shareholders Meeting
    May 12, 2021 1:00 PM EDT

    Cytokinetics, Inc. Annual Shareholders Meeting
    May 12, 2021 1:00 PM EDT
  • Webcast
    X Q1 2021 Cytokinetics, Inc. Earnings Conference Call
    May 6, 2021 4:30 PM EDT

    Q1 2021 Cytokinetics, Inc. Earnings Conference Call
    May 6, 2021 4:30 PM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session
Secondary Analysis From GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session SOUTH SAN FRANCISCO, Calif. , May 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at the American College of Cardiology 70 th Annual Scientific
Toggle Summary Cytokinetics Reports First Quarter 2021 Financial Results
Secondary Analysis from GALACTIC-HF  to be Presented in Late Breaking Clinical Trial Session at ACC.21 Company Plans to Submit NDA for Omecamtiv Mecarbil  following Recent Meeting with FDA Results from REDWOOD-HCM Expected Mid-Year;  Open Label Extension Study and Phase 3 Clinical Trial Planning
Toggle Summary Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing REDWOOD-HCM
SOUTH SAN FRANCISCO, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first site has been activated to enroll patients in REDWOOD-HCM OLE, an open-label extension clinical study designed to assess the long-term safety and tolerability of
Toggle Summary Cytokinetics to Hold Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif. , May 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 12, 2021 at 10:30 AM Pacific Time at the Company’s headquarters, 280 East Grand Avenue , South San

EVENTS

There are currently no events to display.